A case‐matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma

Extraovarian müllerian adenocarcinoma (EOM) resembles primary ovarian carcinoma (POC) both histologically and clinically, yet little is known regarding the molecular genetic characteristics of this entity. The objective of this study was to compare the expression of three molecular markers of tumor behavior in EOMs and POCs.

[1]  I. Campbell,et al.  Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21. , 1996, British Journal of Cancer.

[2]  D. Porteous,et al.  Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. , 1996, Cancer research.

[3]  Cooper,et al.  Prediction of Biologic Aggressiveness in Colorectal Cancer by p53/K-ras-2 Topographic Genotyping. , 1996, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[4]  H. Gabra,et al.  High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. , 1996, British Journal of Cancer.

[5]  P. Schwartz,et al.  Allelic deletion mapping of putative tumor suppressor genes on 17q in sporadic ovarian cancer. , 1995, Journal of obstetrics and gynaecology.

[6]  M. Hung,et al.  HER-2/neu-targeting gene therapy--a review. , 1995, Gene.

[7]  Carissa A. Sanchez,et al.  A p53-dependent mouse spindle checkpoint , 1995, Science.

[8]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[9]  C. Arteaga,et al.  p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. , 1994, Cancer research.

[10]  D. Slamon,et al.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.

[11]  G. Nicolson,et al.  c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. , 1994, Cancer research.

[12]  E. Wilander,et al.  p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. , 1994, Gynecologic oncology.

[13]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[14]  M. Killackey,et al.  Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. , 1993, Gynecologic oncology.

[15]  L. Bloss,et al.  Extraovarian peritoneal serous papillary carcinoma: A case‐control retrospective comparison to papillary adenocarcinoma of the ovary , 1993, Gynecologic oncology.

[16]  M. Carcangiu,et al.  Allelic loss in ovarian cancer , 1993, International journal of cancer.

[17]  A. Thor,et al.  p53 gene mutations and protein accumulation in human ovarian cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Kitchener,et al.  p53 mutation is a common genetic event in ovarian carcinoma. , 1993, Cancer research.

[19]  R. Berkowitz,et al.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. , 1993, Cancer research.

[20]  G. Nicolson,et al.  Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. , 1992, Oncogene.

[21]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[22]  S. Hirohashi,et al.  High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy , 1992, Japanese journal of cancer research : Gann.

[23]  H. Tashiro,et al.  c‐myc over‐expression in human primary ovarian tumours: Its relevance to tumour progression , 1992, International journal of cancer.

[24]  G. Naus,et al.  Prognostic value of flow cytophotometric DNA content analysis in single treatment stage IB-IIA squamous cell carcinoma of the cervix. , 1991, Gynecologic oncology.

[25]  M. Hung,et al.  Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. , 1991, Oncogene.

[26]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[27]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[28]  W. Gullick,et al.  NCL‐CB11, a new monoclonal antibody recognizing the internal domain of the c‐erbB‐2 oncogene protein effective for use on formalin‐fixed, paraffin‐embedded tissue , 1990, The Journal of pathology.

[29]  I. Cohen,et al.  Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. , 1990, Gynecologic oncology.

[30]  D. Gershenson,et al.  Papillary serous carcinoma of the peritoneum , 1990, Obstetrics and gynecology.

[31]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[32]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[33]  A. Ullrich,et al.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.

[34]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Avgeropoulos,et al.  Embryology , 1916, The Indian Medical Gazette.

[36]  M. Miwa,et al.  Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. , 1994, Cancer research.

[37]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[38]  W. Gullick.  4. The role of the epidermal growth factor receptor and the c‐erbB‐2 protein in breast cancer , 1990 .